Implementation and pratical aspects of quantitative decision-making in clinical drug development

Juan J. Abellan; Nicolas Bonnet; Alex Carlton; Paul Frewer; Heiko Götte; John-Philip Lawo; Jesper Madsen; Oliver Sailer; Guido Thömmes; Gaëlle Saint-Hilary

arXiv · 2207.07977

Implementation and pratical aspects of quantitative decision-making in clinical drug development

Juan J. Abellan·Nicolas Bonnet·Alex Carlton·Paul Frewer·Heiko Götte·John-Philip Lawo·Jesper Madsen·Oliver Sailer·Guido Thömmes·Gaëlle Saint-Hilary

View original source ↗Read source document ↗Export metadata ↓

Abstract

Quantitative decision-making (QDM) principles address the issues related to the mapping of results to decisions, the synthesis of information and the quantification of uncertainty. Since the clinical drug development involves a succession of decisions to be made, QDM methods can be applied at various levels. At the study level, it can be used to properly design a study, and improve the decisions that are made either during the trial or at its end. Establishing decision criteria ahead of the study is essential here to address the need for speedy decisions, potentially in real time. At the project level, QDM can be used to inform decisions to continue, adapt or stop a drug development programme based on results from previous studies. At the portfolio level, QDM can be used to choose, prioritise and optimise the development portfolio, e.g. using the probability to reach market access or target sales within a predefined timeline. The increasing interest in QDM and its statistical nature led in 2017 to the development a cross-industry and academia Special Interest Group on QDM within the Society and the European Federation of Statisticians in the Pharmaceutical Industry (PSI and EFSPI). The activities of the group included discussing QDM examples, some published in the literature and some real anonymised ones covering several settings. While the methodologies, and to some extent the terminology, employed also varied depending on the context, discussions within the group distilled common principles to be considered when implementing QDM, particularly around the construction of QDM frameworks, assessment of operating characteristics and communication with the clinical team. The present manuscript presents those points to consider, hoping they can be helpful to statisticians interested in implementing QDM.

Explore related subjects

stat.AP stat.ME

Keep this discovery

BibTeX RIS

Juan J. Abellan, Nicolas Bonnet, Alex Carlton, Paul Frewer, Heiko Götte, John-Philip Lawo, Jesper Madsen, Oliver Sailer, Guido Thömmes, Gaëlle Saint-Hilary. 2022-07-16. Implementation and pratical aspects of quantitative decision-making in clinical drug development. https://arxiv.org/abs/2207.07977

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

Privacy-Preserving Causal Meta-Mediation Analysis with Survival Outcomes

Privacy and data-governance constraints often prevent pooling individual-level data across studies, limiting the use of conventional approaches for causal media- tion analysis in multicenter settings. We propose a federated causal meta-mediation framework for right-censored time-to-event outcomes that enables collaborative es- timation without sharing individual-level data. Our framework targets natural indirect effects in a prespecified population by combining information on mediator and outcome mechanisms across distributed data sources. A site-by-site identifi- cation strategy further allows heterogeneity across data sources to be character- ized, with a variance decomposition separating outcome-related, mediator-related, and interaction components. We develop federated one-step and targeted maxi- mum likelihood estimators that accommodate data-adaptive and machine-learning methods for nuisance-function estimation. The finite-sample performance of the proposed estimators is evaluated through numerical simulations. To illustrate the practical utility of the framework, we apply it on data from the French National Health Data System to evaluate the role of methotrexate coprescription in explain- ing the effect of TNFi versus IL-12/23 inhibitor therapy on treatment persistence among psoriatic patients.

stat.AP↗

arXiv2026

Geospatial Foundation Models Capture Health-Relevant Dimensions of Place Beyond Conventional Social Risk Indices

Area-based social risk indices summarize residents' socioeconomic conditions but incompletely capture physical features of place that may affect health. We evaluated whether numerical representations of physical place produced by four geospatial foundation model families from 2022 satellite data explained residual variance in tract-level associations between the Area Deprivation Index, Social Deprivation Index, and Social Vulnerability Index with health outcomes. We used LightGBM to predict variables from the American Community Survey and 40 chronic disease and health-behavior outcomes from CDC PLACES across 82,646 census tracts in the contiguous United States, evaluating performance across 10 held-out states. Among survey variables, models were moderately predictive of some variables including housing type (R-squared up to 0.54) but weak for disability, unemployment, and income disparity. For health outcomes, models explained up to 54% of variance left unexplained by social risk indices, with the largest gains for annual checkups, arthritis, and high blood pressure. Mean total variance explained by geospatial foundation models across the 40 health-related outcomes increased from 0.31 in the smallest tract-size decile to 0.39 in the largest. Geospatial foundation models capture health-relevant features of place not represented by conventional social risk indices and may usefully augment them in epidemiological analyses.

stat.AP↗

arXiv2026

A spatiotemporal negative binomial model with dynamic dispersion: An application to Tuberculosis infections

Tuberculosis (TB) remains a critical public health concern in Brazil, characterized by pronounced spatial heterogeneity and fluctuating temporal volatility. In this paper, we study monthly TB notifications across 61 microregions of Sao Paulo state from 2001 to 2024. To do this, we introduce a negative binomial spatial integer-valued generalized autoregressive conditional heteroskedastic (INGARCH) model featuring jointly dynamic conditional means and time-varying dispersion. To capture inter-regional spillovers, we incorporate both discrete adjacency structures and a novel continuous distance-based formulation leveraging the Matern correlation function. Parameter estimation via conditional maximum likelihood employs a two-step profile-likelihood iterative scheme, demonstrating solid finite-sample performance in simulation studies. Applied to the Sao Paulo TB surveillance data, the framework substantially outperforms standard Poisson and fixed-dispersion spatiotemporal baselines in empirical fit and uncertainty quantification, maintaining nominal 95% predictive coverage across both dense metropolitan centers and rural microregions. Our results reveal marked spatial heterogeneity in baseline incidence, dynamic overdispersion driven by localized outbreaks, and short-range spatial interaction decay. By accurately modeling spatiotemporal volatility, the proposed methodology provides a robust statistical tool to support public health surveillance, policy-making, and resource allocation.

stat.AP↗